Overview
During this webinar we will:
- review ROS1 epidemiology.
- appraise optimal testing.
- review treatment results with different ROS inhibitors.
- identify the mechanisms of acquired resistance to ROS1 inhibitors.
- look forward to the potential next steps in the management of this disease.
- Demonstrate new targetable molecular subtype, ROS1, a distinct group of patients for which new treatments are now available.
- Appraise optimal molecular testing to determine the profile of individual patients and selection for specific, active therapeutic approaches.
- Identify the mechanisms of acquired resistance to ROS1 inhibitors.
Federico Cappuzzo, MD
Director of Medical Oncology, Department of Medical, Oncology and Hematology, Ospedale Santa Maria delle Croci, Ravenna, Italy.
Enriqueta Felip, MD
Chief Thoracic Medical Oncology, Associate Professor, Vall d'Hebron University Hospital, Barcelona, Spain.
For any inquiries, please contact meetings@iaslc.org.
- Demonstrate new targetable molecular subtype, ROS1, a distinct group of patients for which new treatments are now available.
- Appraise optimal molecular testing to determine the profile of individual patients and selection for specific, active therapeutic approaches.
- Identify the mechanisms of acquired resistance to ROS1 inhibitors.
Federico Cappuzzo, MD
Director of Medical Oncology, Department of Medical, Oncology and Hematology, Ospedale Santa Maria delle Croci, Ravenna, Italy.
Enriqueta Felip, MD
Chief Thoracic Medical Oncology, Associate Professor, Vall d'Hebron University Hospital, Barcelona, Spain.
For any inquiries, please contact meetings@iaslc.org.